leisure time -WSS

leisure time

author：knowledge 2025-08-12 08:30:19 - browse：131

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Weight loss drugs aren’t covered by Obamacare. That may change

hotspot

explore

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Eli Lilly’s Mounjaro succeeds in second weight

Ukraine seeks to reclaim its role as a hub for clinical trials

Congress may force more Covid

WATCH: Why do our ears pop?

FDA warns medical device makers about rise in fabricated data

focus

leisure time

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

ChatGPT in medicine: STAT answers readers' burning questions

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

At least 13 dead in Texas as scorching temps continue

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

After affirmative action ruling, medical educators look to 'holistic review'

Mom launches Girl Scout troop for LGBTQ youth in Texas

focus

Patients, doctors are clashing about side effects of hormonal birth control

Measles policy set amid Florida outbreak alarms vaccine proponents

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Surprise medical billing ban raises prices elsewhere

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Flagship Pioneering startup Sonata Therapeutics lays off 21

leisure time

hotspot

explore

hotspot